Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03320018 · ClinicalTrials.gov registry record · Phase 2
Neuroprotection in Acute Ischemic Stroke
A Phase 2 study, sponsored by Stony Brook University.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT03320018: Completed Phase 2 study, sponsored by Stony Brook University.
NCT03320018 is a Phase 2 study that has completed, run by Stony Brook University. The registered enrollment target is 15 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03320018, a Phase 2 study, has completed, sponsored by Stony Brook University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
This is a pilot randomized control trial (RCT) to explore the possible beneficial effect of a novel combination therapy consisting of molecular hydrogen H2 plus minocycline ("H2M"), on neurological recovery after acute ischemic stroke.
Primary Outcome
rating scale to assess level of functional independence for patients post-stroke. Scores range from 0 (no symptoms) to 6 (dead). mRS scores at 90 days will be classified as favorable or unfavorable based on the baseline NIHSS measured at time of enrollment. Subjects in the lowest baseline severity tertile (NIHSS 5-7) will need to have a 90 day mRS score of 0 to be considered to have a favorable outcome. Subjects with baseline NIHSS 8-14 will need a 90 day mRS score 0-1 to be considered to have
Interventions
- DRUG Hydrogen
- DRUG Minocycline
- OTHER Placebo Hydrogen
- OTHER Placebo Minocycline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2017-08-02 |
| Est. Completion | 2019-08-13 |
| Phase | Phase 2 |
What the finished NCT03320018 record still lists
NCT03320018 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 4 interventions - of which Hydrogen is the first listed.
NCT03320018 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03320018 about?
NCT03320018 is a clinical study titled "Neuroprotection in Acute Ischemic Stroke". This is a pilot randomized control trial (RCT) to explore the possible beneficial effect of a novel combination therapy consisting of molecular hydrogen H2 plus minocycline ("H2M"), on neurological recovery after acute ischemic stroke.
What is the current status of trial NCT03320018?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2017-08-02. Estimated completion is 2019-08-13.
What interventions are being tested in trial NCT03320018?
The interventions under investigation include: Hydrogen (DRUG), Minocycline (DRUG), Placebo Hydrogen (OTHER), Placebo Minocycline (OTHER).
Who is sponsoring clinical trial NCT03320018?
This trial is sponsored by Stony Brook University, which has 127 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03320018's enrollment target sits among peer trials
15 1919th of 2000 higher than 60 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI